{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:41:44Z","timestamp":1791650504828,"version":"4.3.4"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Graves\u2019 Ophthalmopathy (GO), or thyroid eye disease, is an extrathyroidal complication of Graves\u2019 disease, causing a significant impact on patients\u2019 quality of life. There are consensus statements from both the American Thyroid Association (ATA) and the European Group on Graves\u2019 Orbitopathy (EUGOGO) which provide guidance in management. However, there remain areas of ongoing debate and evolution in treatment approaches. This systematic review aims to evaluate immunomodulatory drugs in the treatment of GO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The following databases were searched: Cochrane (CENTRAL), Embase, MEDLINE, ProQuest, PubMed, SCOPUS, and Web of Science. The last date of searching for each database was 10th October 2025. All primary studies on human patients with GO, treated with newer, targeted immunomodulatory therapies, in particular biologics and\/or disease-modifying antirheumatic drugs, were included. Studies in languages other than English were excluded. The primary outcome of interest was Clinical Activity Score (CAS). A narrative synthesis was performed, including CAS and four other secondary outcomes. Cochrane risk of bias tools were used to assess quality of evidence. The study is registered on PROSPERO (CRD42023400285).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 4839 records identified, 41 were eligible for data extraction. Teprotumumab and tocilizumab showed benefit in reducing CAS and proptosis, whilst rituximab was inconclusive. Methotrexate and reduced-dose steroids were beneficial in reducing CAS, and both methotrexate and cyclosporine with steroids were good for reducing proptosis. However, effects of immunomodulation on other secondary outcomes were unclear. Adverse events were higher in the steroid treated patients compared to all other drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologics and steroid-sparing agents may be more effective than steroids at reducing CAS, but this is limited by the lack of head-to-head comparisons between drugs and significant heterogeneity amongst the included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42023400285.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1686786","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:21:58Z","timestamp":1770700918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunomodulators in Graves\u2019 ophthalmopathy: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Antoinette","family":"Yeung","sequence":"first","affiliation":[{"name":"Ear, Nose and Throat Surgery, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Saqlain","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"National Health Service, University of Birmingham Medical School","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neginsadat","family":"Mirtorabi","sequence":"additional","affiliation":[{"name":"Ear, Nose and Throat Surgery, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umnia Nasir","family":"Ahmed","sequence":"additional","affiliation":[{"name":"National Health Service, University of Birmingham Medical School","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Watts","sequence":"additional","affiliation":[{"name":"Ear, Nose and Throat Surgery, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Ear, Nose and Throat Surgery, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Kumari","sequence":"additional","affiliation":[{"name":"Ophthalmology, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien","family":"Boelaert","sequence":"additional","affiliation":[{"name":"Department of Applied Health Sciences, University of Birmingham","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"Ear, Nose and Throat Surgery, University Hospitals Birmingham National Health Service (NHS) Foundation Trust","place":["Birmingham, United Kingdom"]},{"name":"Department of Applied Health Sciences, University of Birmingham","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, University of Birmingham","place":["Birmingham, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0097-2","article-title":"Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2010.03.010","article-title":"Thyroid eye disease","volume":"28","author":"Cockerham","year":"2010","journal-title":"Neurol Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7462.385","article-title":"Recent developments in thyroid eye disease","volume":"329","author":"Cawood","year":"2004","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for graves\u2019 Ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves\u2019 orbitopathy","volume":"44","author":"Diana","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-012-0256-9","article-title":"Thyroid eye disease: towards an evidence base for treatment in the 21st century","volume":"12","author":"Gillespie","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for graves\u2019 Orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e31814a5ef8","article-title":"Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease","volume":"27","author":"Zoumalan","year":"2007","journal-title":"J Neuro-Ophthalmol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000128","article-title":"Thyroid eye disease","volume":"34","author":"Bhatti","year":"2014","journal-title":"J Neuro-Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027760","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B15","unstructured":"FDA approves first treatment for thyroid eye disease\n          \n          2020"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1260013","article-title":"High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/thy.1995.5.185","article-title":"MR T2 relaxation time for the assessment of retrobulbar inflammation in graves\u2019 Ophthalmopathy","volume":"5","author":"Utech","year":"1995","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/thy.1996.6.283","article-title":"Effects of octreotide treatment on graves\u2019 Ophthalmopathy and circulating sICAM-1 levels","volume":"6","author":"Ozata","year":"1996","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0697","article-title":"Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy","volume":"89","author":"Dickinson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702393","article-title":"Avoiding surgery for thyroid eye disease","volume":"20","author":"Meyer","year":"2006","journal-title":"Eye"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1105","article-title":"Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of graves\u2019 Ophthalmopathy","volume":"91","author":"Stan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2008.02.013","article-title":"New immunomodulators in the treatment of Graves\u2019 ophthalmopathy","volume":"69","author":"Salvi","year":"2008","journal-title":"Ann Endocrinol (Paris)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/IOP.0b013e3181c4dfde","article-title":"Rituximab for thyroid eye disease","volume":"26","author":"Silkiss","year":"2010","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/01676831003660663","article-title":"The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease","volume":"29","author":"Tambe","year":"2010","journal-title":"Orbit"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 Orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with graves\u2019 Orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","journal-title":"Graefe s Arch Clin Exp Ophthalmol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","article-title":"Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a Mexican population","volume":"81","author":"Ceballos-Mac\u00edas Jos\u00e9","year":"2020","journal-title":"Annales d\u2019Endocrinolo"},{"key":"B40","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant graves\u2019 Orbitopathy treated with tocilizumab in real-world clinical practice: A 9-year single-center experience","volume":"10","author":"P\u00e9rez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002027","article-title":"Tocilizumab for the management of thyroid-associated orbitopathy","volume":"38","author":"Smith","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14655","article-title":"Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab","volume":"97","author":"Moi","year":"2021","journal-title":"Clin Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2021","journal-title":"Eye"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2021.1933081","article-title":"Teprotumumab for chronic thyroid eye disease","volume":"41","author":"Ozzello","year":"2021","journal-title":"Orbit"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant graves\u2019 Orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2020","journal-title":"Ocular Immunol Inflammat"},{"key":"B47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaophthalmol.2022.3779","article-title":"Doxycycline vs Placebo at 12 Weeks in Patients With Mild Thyroid-Associated Ophthalmopathy","volume":"140","author":"Pan","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0017","article-title":"Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves\u2019 orbitopathy","volume":"11","author":"Shen","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease patients with long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1079852","article-title":"Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study","volume":"13","author":"Wang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/IOP.0000000000002564","article-title":"Teprotumumab for the treatment of recalcitrant thyroid eye disease","volume":"40","author":"Men","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eprac.2024.08.005","article-title":"Effects of teprotumumab and role of human leukocyte antigens markers in patients with thyroid eye disease","volume":"30","author":"Hoang","year":"2024","journal-title":"Endocr Pract"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002531","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14080791","article-title":"One incremental stride for doxycycline, one substantial advancement for thyroid eye disease","volume":"14","author":"Matoc","year":"2024","journal-title":"Diagnos (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03143-4","article-title":"Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort","volume":"44","author":"Habroosh","year":"2024","journal-title":"Int Ophthalmol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03117-6","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee","year":"2024","journal-title":"Int Ophthalmol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002707","article-title":"Effects of teprotumumab on eyelid retraction in thyroid eye disease","volume":"41","author":"Al-Sharif","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2025.2452181","article-title":"Tocilizumab \u2013 a disease-modulating treatment for thyroid associated ophthalmopathy","volume":"44","author":"Farde","year":"2025","journal-title":"Orbit"},{"key":"B60","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Regional Health - Western Pac"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 Orbitopathy: A randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of graves\u2019 Orbitopathy: A meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B63","volume-title":"European medicines agency","year":"2018"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605624","article-title":"Cancer risk in patients hospitalized for Graves' disease: a population-based cohort study in Sweden","volume":"102","author":"Shu","year":"2010","journal-title":"Br J Can"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe graves\u2019 Ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cen.13834","article-title":"Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach","volume":"89","author":"Sipkova","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1334","article-title":"Octreotide (Long-acting release formulation) treatment in patients with graves\u2019 Orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study","volume":"90","author":"W\u00e9meau","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF03344124","article-title":"Slow-release lanreotide in Graves\u2019 ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial","volume":"29","author":"Chang","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/285698","article-title":"Efficacy of subantimicrobial dose doxycycline for moderate-to-severe and active graves\u2019 Orbitopathy","volume":"2015","author":"Lin","year":"2015","journal-title":"Int J Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.24245\/mim.v38i3.5764","article-title":"Effectiveness of methylprednisolone combined with doxycycline to reduce the clinical activity of Graves orbitopathy","volume":"38","author":"Mendoza-Mart\u00ednez","year":"2022","journal-title":"Med Int M\u00e9x"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/jpm14101027","article-title":"Teprotumumab for the treatment of thyroid eye disease: why should we keep our eyes \u201cWide open\u201d?\u2014A clinical and pharmacovigilance point of view","volume":"14","author":"Martel","year":"2024","journal-title":"J Pers. Med"},{"key":"B74","volume-title":"European medicines agency (EMA)","year":"2025"},{"key":"B75","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcjo.2020.07.020","article-title":"Treatment of corticosteroid resistant thyroid eye disease with subcutaneous tocilizumab","volume":"56","author":"Silkiss","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.49.NSA5.2","article-title":"Small molecule agonists and antagonists as potential new therapeutics targeting the TSH receptor","volume":"49","author":"Neumann","year":"2017","journal-title":"Endocr Abstracts"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1686786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:22:00Z","timestamp":1770700920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1686786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":76,"alternative-id":["10.3389\/fendo.2026.1686786"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1686786","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1686786"}}